Drugs / GD2-SADA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05130255 | Nov 2022 → Mar 2026 | melanoma, neuroblastoma, sarcoma, small cell lung carcinoma | Y-mAbs Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-05-28 | Y-mAbs Therapeutics | Results Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline ymabs.com ↗
Both the GD2-SADA and 177Lu-DOTA administrations were generally safe and well-tolerated. |
| 2025-01-31 | Y-mAbs Therapeutics | Results Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting ymabs.com ↗
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and American College of Nuclear Medicine (ACNM) Annual Meeting being held on January 30 to February 1, 2025 in Anaheim, California. |
| 2025-01-10 | Y-mAbs Therapeutics | Results Y-mAbs Provides Strategic Business Update and 2025 Priorities ymabs.com ↗
Preliminary data from the Part A GD2-SADA Phase 1 trial has demonstrated this novel pre-targeting approach to be well-tolerated with no dose-limiting toxicities (DLTs) and no treatment-related adverse events (AEs) reported. |
| 2025-01-10 | Y-mAbs Therapeutics | Results Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities ymabs.com ↗
Preliminary data from the Part A GD2-SADA Phase 1 trial has demonstrated this novel pre-targeting approach to be well-tolerated with no dose-limiting toxicities (DLTs) and no treatment-related adverse events (AEs) reported. |
| 2024-09-06 | Orphan Australia | Results Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research serb.com ↗
In a preclinical model of neuroblastoma, also presented in the poster, the chelated radioisotope is administered during the second step of PRIT and binds to GD2-SADA on tumor cells, delivering cytotoxic radiation with minimal off-target exposure. |
| 2024-09-06 | Y-mAbs Therapeutics | Results Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research ymabs.com ↗
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. |
| 2024-06-07 | Y-mAbs Therapeutics | Results Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting ymabs.com ↗ |
| 2024-06-01 | Y-mAbs Therapeutics | Results Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting ymabs.com ↗
In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors. |
| 2022-07-12 | Y-mAbs Therapeutics | Regulatory Y-mAbs’ Announces Clearance of IND for GD2-SADA ymabs.com ↗ |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2-SADA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05130255 ↗ |
| Route | Intravenous | “GD2-SADA IV at 0.3 mg/kg followed by 30 mCi 177Lu-DOTA IV” NCT05130255 ↗ |